Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

Fig. 1

Study design. Asterisk indicates patients could discontinue after the short-term treatment period and continue to follow-up. Dagger indicates patients receiving adalimumab switched to abatacept at week 28, following a 6-week washout period (4-week biologic-free window). CCP2, cyclic citrullinated peptide 2; MTX, methotrexate; MTX-IR, inadequate response to methotrexate; PO, orally; R, randomization; RA, rheumatoid arthritis; RF, rheumatoid factor; SC, subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us